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1. Introduction
1.1. Ocular anatomy
In  order  to  understand the pathophysiology of  this  condition we will  describe the uvea
anatomy.
The Iris is a contractile diaphragm that controls the degree of retinal illumination, it has a
central aperture, the pupil, located slightly nasally. It consists of the following layers from
anterior to posterior:
1. Stroma: a thin avascular layer with fibroblasts and melanocytes. It is heavily pigment‐
ed in persons with brown eyes less pigmented in green and hazel irises and least in
blue. Posteriorly, the stroma contains the sphincter pupillae muscle (parasympathetic,
miosis).
2. Pigment epithelium: consists of 2 layers of cells: -anterior layer, which intermingles
with the dilator pupillae muscle (sympathetic, mydriasis) -posterior layer, which is con‐
tinuous with the pigment epithelium of the ciliary body and RPE of the retina, all hav‐
ing the same embryologic origin.
The cilliary body is one of the three parts of the uvea and extends for 6 mm from the end of
the retina (ora serrata) till the scleral spur. Its epithelial portion (adjacent to vitreous) con‐
sists of a posterior portion (pars plana) and an anterior portion (pars plicata). The latter has
60-70 folds called the ciliary processes which secrete the aqueous humor into the posterior
chamber. Its uveal portion contains the ciliary muscle which has 3 parts, all under parasym‐
pathetic innervation: longitudinal (outermost), radial and circular.
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The choroid is a dark brown vascular sheet, 0.25mm thick, lying between the sclera and the
retina. The outer vascular bed has large vessels (layer of Haller) and the inner bed consists
of an extensive network of fenestrated vessels, the choriocapillaris which is the major blood
supply to the outer layers of the retina and to the whole macula The inner layers, up to the
middle of the Pigmented Epithelium are supplied by the central retinal artery.
1.2. Difference between ocular melanoma and cutaneous melanoma
Ocular and cutaneous melanomas show several differences despite they both derive from
melanocytes. Both malignancies show a high tendency to metastasize though they display
different preferential sites. Skin melanomas spread to distant skin sites, lung, liver, central
nervous system and bone. However uveal melanoma, the most frequently diagnosed of the
ocular melanomas, gives rise to metastases almost exclusively in the liver which is affected
in 90% of the cases.
Interestingly, both malignancies display similar chromosomal aberrations as well as a simi‐
lar gene expression profile [1]. The similarity in this aspect, despite the difference in tumor
behaviour, serves as a proof of the role of the microenvironment in tumor development.
With respect to the early diagnosis, in the skin melanoma the suspected diagnosis and the
subsequent clinical follow-up are based on the ABCDE rule.On the other hand, in the diag‐
nosis of ocular melanoma the most relevant information comes from the ophthalmoscopy
and the ultrasonography. Finally, consulting times for patients and prognosis are different
for both types of melanoma.
2. Objectives
In this chapter we will focus in the clinical management of ocular melanoma from the diag‐
nosis to the treatment.
3. Immunopathology
The eye is an immunologically privileged site; from an evolutionary point of view this con‐
dition helps to control or eliminate pathogens while generating the least inflammatory dam‐
age to the ocular tissues. However, the counterpart of this phenomenon is that it favors the
escape of the tumor cells from the controls of the immune system, facilitating the growth of
the uveal melanoma and its metastatic dissemination. Experiments in mice it have shown
that cytotoxic cell activity in the ocular tissue might be modulated by two mechanisms:
1. By direct interference of the specific effector function of CD8 + lymphocytes.
2. Indirectly affected by stimulation of macrophages [2].
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The inhibition of macrophage action was expressed by an insufficient production of nitric
oxide in the ocular tissue, which is known to modulate the tumoricidal activity of cytotoxic
T lymphocytes [3]. It has also been shown that tumor rejection in mice by the CD8 + CTL is
mediated by TNF-α [4].
The study of the mechanisms that facilitate the growth of an immunogenic tumor in the
anterior chamber, demonstrated an influx of CD8 + CTL infiltrating the tumor. This phe‐
nomenon was preceded by intratumoral accumulation of CD11 + myeloid cells B, which
exert a powerful immunosuppressive activity on the CTL, facilitating tumor escape from
the immune system. Regulatory T cells,  myeloid suppressor cells and stroma cells could
also reduce the delayed type hypersensitivity reaction to induce apoptosis of CD8 + and
NK cells [5]
4. Demographic and epidemiological data
The racial background of the patient is an important factor. Whites have been shown to be
eight times more likely to develop choroidal melanoma than African-Americans. This trend
is also observed in skin melanoma, whites are six times. More likely to develop this malig‐
nancy than African-Americans [6-7]. The individuals with light iris are at increased risk of
developing uveal melanoma. This is a finding that implicates sunlight exposure as an impor‐
tant environmental risk factor. The protective effect of melanin may be particularly impor‐
tant in the iris as it is the only part of the uveal tract positioned in front of the lens, which
serves as an effective ultraviolet filter.
The  median  age  at  diagnosis  is  about  55-65  years  and  the  incidence  decreases  after  70
years of age. With regards to incidence depending on sex, there is a slight predominance
of males [8].
In a study involving 4500 patients with uveal melanoma, only 0.6% of the cases had a family
history of this disease [9]. Thus heredity does not seem to be a significant determinant of
uveal melanoma. With respect to occupational and chemical exposures, the only specific occu‐
pational exposure that has been linked to uveal melanoma is welding. Ocular melanomas
have been induced in laboratory animals after administration of radium, methylcholanthrene,
N-2fluorenylacetamide, ethionine and nickel subsulfide.
5. Diagnosis of ocular melanoma
Accuracy in the early diagnosis of ocular melanoma is crucial to improve the prognosis.
Currently the diagnosis of ocular melanoma is based on both the clinical experience of the
specialists and on the use of modern diagnostic techniques.
The rate of misdiagnosis for eyes enucleated for choroidal melanoma was 20 % until the
1970’s but it has decreased to 1% since then. [10-16]
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5.1. Clinical
The most common symptoms include visual loss, photopsias and visual field defects. None of
these symptoms are specific of choroidal melanoma. Pain is very atypical in ocular melano‐
ma, except in those cases that present massive extraocular extension, inflammation or neo‐
vascular glaucoma.
Indirect Ophthalmoscopy through a well-dilated pupil is the most important examination in
the diagnosis of choroidal melanoma. The classic image is a pigmented, dome-shaped or col‐
lar button-shaped tumor in a minority of cases and an associated exudative retinal detach‐
ment, orange tumor pigmentation (Lipofuscin) and sentinel vessels (prominent epiescleral
vessels especially in those involving ciliary body). Scleral transillumination has been advo‐
cated by Reese. [17]
The lesions most commonly mistaken for choroidal melanoma are choroidal nevus (49%),
periphereal exudative hemorrhagic chorioretinopathy (8%), congenital hypertrophy of the
retinal pigment epithelium (6%), hemorrhagic detachment of the retina or pigment epithe‐
lium (5%), circumscribed choroidal hemangioma (8%) and age related macular degenera‐
tion (4%) [18]
5.2. Complementary studies
Ultrasonography: The most important ancillary test in the evaluation of a patient with intra‐
ocular mass lesions is the combination of both A-mode and B-mode ultrasonography (see
Box 1). For tumors larger than 3 mm in thickness, a combination of both scans in skilled
hands can diagnose choroidal melanomas with greater than 95% accuracy [19].
A-mode:
1. medium to low internal echoes with smooth attenuation.
2. vascular pulsations within the tumor
B-mode: 3 classic futures
1. Low to medium reflectivity within the melanoma.
2. Choroidal excavation.
3. Shadowing in the orbit.
Box 1. Ultrasonography
Fluorescein angiography: Early hyperfluorescence with late leakage and multifocal punctate
hyperfluorescence. This study is of major importance in order to distinguish lesions that
simulate choroidal melanoma.
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Other studies like Optical Coherence Tomography and Indocyanine Green angiography
may be useful in the diagnosis of this pathology. Magnetic resonance imaging, nuclear mag‐
netic resonance spectography, color Doppler ultrasonography, electrophysiologic testing
and inmmunologic testing do not offer reliable results. [20-26]
6. Current medical management of patients with Ocular Melanoma
a. Cytogenetic: Personalized Targeted Therapy
Currently much effort is directed toward understanding uveal melanoma genetics and ge‐
nomics [27], hoping that this knowledge will contribute to the development of effective mo‐
lecular therapies
Inhibitors of B.Raf and MEK kinases hold promise for treatment of cutaneous melanomas
harboring BRAF mutations. BRAF are rare in ocular melanomas, but somatic mutations in
the G protein alfa subunits G alfa q and G alfa 11 (encoded by Gnaq and Gna11, respectively)
occur, in a mutually exclusive pattern, in 80% of uveal melanomas. The impact of the B-Raf
inhibitor PLX4720 and the MEK inhibitor AZD6244, the AKT inhibitor MK2206 and the PKC
inhibitors bisindolylmaleimide I (GF109203X) has been assessed [28].
A randomized phase II study compared MEK inhibition (AZD6244) to temozomide in ad‐
vanced uveal melanoma. MEK inhibition seems to be a rationale therapeutic strategy in
uveal melanoma, using Gnaq/11 as a potential predictor of sensitivity [29].
b. Surgery: Resection/Enucleation
Enucleation is indicated when the tumor size exceeds 16 mm of base and 10 mm of height, is
diffuse and with bad prognosis; however it is very important to emphasize that there is no
scientific evidence of increased survival after enucleation. Also, enucleation does not pre‐
vent metastases.
A novel minimally invasive surgical technique for resection of selected cases of small iris tu‐
mours has been described. This technique avoids the potential morbidity associated with a
large corneoescleral incision allowing for rapid visual recovery [30].
Radiotherapy, Brachytherapy (BT: I125, 103 Pd, 131 Cs, Ru) and Proton Beam Radiotherapy
(PBRT)
The most commonly employed form of radiotherapy has been the application of an epiescl‐
eral radioactive plaque and the most frequently employed isotopes include 60 Co (Cobalt),
106 Ru (Ruthenium), 192 Ir ( Iridium) and 125 I (Iodine) [31-32].
It is extremely important to highlight the conservative treatment of melanoma, proposed by
Irarrazabal A. et al using brachytherapy. This procedure has shown positive results in pre‐
serving the eye, without increase in mortality. Moreover useful vision was retained in more
than half of the treated patients [33].
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In a study comparing patients treated with Ruthenium brachytherapy with patients undergo‐
ing simultaneous thermotherapy or BT alone, combined treatment provided higher local
control, eye globes preservation, better recurrence-free survival rates, lower rates of metasta‐
ses and prolonged survival than treatment with BT alone.
I125 episcleral brachytherapy in uveal melanoma is effective in tumor control, allowing
preservation of the eye and useful visual function for the majority of patients [34].
It has been suggested that length of remaining life after diagnosis of uveal melanoma is sim‐
ilar following enucleation (removal of the eye) to local eye-conserving radiotherapy. The
multidisciplinary COMS Group emphasized that there were no differences in survival out‐
comes and a small difference in quality-of-life outcomes between patients in the brachyther‐
apy arm and those in the enucleation arm [35].
Radiation  treatment  was  found  to  reduce  the  tumor  in  94%  of  the  cases.  Mean  tumor
thickness decreased from 3.7 to 2.5 and 2.1 after 3 and 5 years respectively. Recurrence oc‐
cured in  6% of  the  treated patients.  Although this  therapy is  associated with complica‐
tions like radiation optic neuropathy in 81% and vitreous bleeding in 30% of cases, it is a
promising  treatment  given  that  enucleation  was  necessary  in  only  3%  of  patients  and
metastasis developed in 15% during follow up. Even though the visual acuity decreases
considerably after optic disc irradiation with proton beam therapy, the rates of tumor con‐
trol and eye retention are favourable.
The second most frequent method of radiotherapy is the use of heavy ions such as Proton
Beam Radiotherapy [36]. In a comparison of the efficacy of PBRT and Ruthenium-106 notched
plaque radiotherapy with or without TTT for the treatment of juxtapapillary choroidal mela‐
noma, it was found that the tumors were successfully treated using either proton beam or
notched plaque combined with adjuvant TTT [37].However, vision is often sacrificed. On
the other hand, Notched plaque alone is not as efficient in reducing the tumor but results in
improved visual outcome [37].
Proton beam irradiation of uveal melanoma has great advantages over brachytherapy be‐
cause of the homogenous dose delivered to the tumor and the possibility of sparing normal
tissue close to the tumor. Complications such as retinal detachment, maculopathy, papillop‐
athy, cataract, glaucoma, vitreous hemorrhage and dryness are described. The severest com‐
plication that usually leads to secondary enucleation is neovascular glaucoma and it is
encountered after irradiation of large to extra-large tumors. It is hypothesized that the resid‐
ual tumor scar may produce proinflammatory cytokines and Vascular endothelial growth
factor- VEGF (toxic tumor syndrome) leading to intraocular inflammation and neovascular
glaucoma. Additional treatments after proton beam such as transpupillary thermotherapy,
endoresection of the tumor scar or intravitreal injections of anti-VEGF may reduce the rate
of these complications [38].
c. Monoclonal Antibodies
Current systemic treatments for metastatic uveal melanoma have not improved overall sur‐
vival. The fully human anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) monoclonal anti‐
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body, ipilimumab, improved overall survival of patients with advanced cutaneous melanoma
in a phase 3 trial. However, uveal melanoma patients were excluded from this study. A sub‐
analysis, performed by the ipilimumab-ocular melanoma expanded access program (I-
OMEAP) study group, aimed at assessing the activity and safety of ipilimumab in patients
with uveal melanoma in a setting similar to daily clinical practice. The results indicated that
uveal melanoma is a potential target for ipilimumab treatment and that it should be further
investigated in clinical trials [39].
The R24 monoclonal antibody, that recognizes the disialoganglioside GD3 expressed on the
surface of malignant melanoma cells, could mediate destruction of these cells. A combina‐
tion of R24 with a low dose of IL-2 was found to promote destruction of cultured melanoma
cells and it can be safely administered to patients with metastatic melanoma [40].
d. Transpupillary Thermotherapy (TTT):
Choroidal melanomas should be diagnosed and treated at the very early stage as the initial
spread of metastases is thought to occur during the proliferative stage of tumor develop‐
ment.
TTT is recomended for the management of posterior choroidal nevi suspected for malignant
transformation or small choroidal melanomas that are less than 2-5 mm in thickness [41].
TTT might be the treatment of choice for selected, very small melanomas. However, studies
with long follow-up and large number of patients are needed to evaluate its effectiveness.
Choroidal melanomas treated with TTT as stand-alone procedure need a close monitoring
since these tumors developed a significant rate of local recurrences and ocular side-effects in
the long run.
e. Antiangiogenic drugs (Bevacizumab)
Anti-angiogenic therapy is based on the assumption that a tumor cannot grow beyond the
limits of diffusion (about 1-2 mm) of oxygen and nutrients from capillaries, unless angiogen‐
esis takes place. VEGF plays a key role in angiogenesis, regulating vasopermeability and the
proliferation and migration of endothelial cells. VEGF levels are significantly elevated in
uveal melanoma patients with metastatic disease compared to patients without metastases.
Anti-angiogenic therapy, such as bevacizumab, is currently used for the treatment of meta‐
stases of several malignancies. [43].
Bevacizumab may be used as an adjuvant agent when used following plaque brachyther‐
apy in the treatment of choroidal melanoma. The combination of this treatments was as‐
sessed  in  an  interventional  case  series  of  100  patients  treated  from  2006-2008  for
choroidal  melanoma and the results  were satisfactory.  Melanoma specific  mortality  was
0% at 9 months after treatment. Mean visual acuity for combined treatment at 6 months
was 20/30 [42]
The bevacizumab - radiotherapy combination could be a promising clinical approach for the
management of human uveal melanoma, since it may allow the use of lower doses of radio‐
therapy without compromising the antitumor effect [44].
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f. Chemotherapy
There is no current evidence that chemotherapy has a significant role in the primary man‐
agement of uveal melanoma. Such treatment may prolong survival for a few months but it is
unlikely that it will be curative.
Uveal melanoma metastases develop in 6.5-35% of patients, most commonly to the liver.
Metastatic uveal melanoma survival is poor, with 5-7 months of median survival. A ret‐
rospective study including 58 patients with uveal melanoma metastases showed that the
median overall survival (OS) for all the patients was 10.83 months. Patients who had un‐
dergone chemotherapy presented 10.83 months of median OS whereas the patients who
did  not  undergo  this  treatment  had  an  OS  of  8.033  months.  Patients  with  metastatic
uveal melanoma should be included in clinical trials evaluating other options with new‐
er agents [45].
g. Others (Adjuvant therapy with interferon, Imatinilo Mesylate, Paclitaxeldocosahexae‐
noico Acid, Factionated Radiosurgery Cyberknife, aflibercept, vaccine).
7. Medical prognosis: Mortality (Hepatic metastasis), loss of the eye, loss
of vision
These three variables will affect directly the patient survival:
Variable Importance for prognosis
A Size (Base more than 16 mm and altura more than 10 mm). +
B Cell Type (Epithelloid Cells) ++
C Genetic Type (GEP: Gene Expression Profile) +++
Prognosis: GEP (Gene Expression Profile) In a prospective evaluation involving 514 uveal
melanoma patients [46], the gene expression profile prognostic assay helped in classifying
the primary tumor into two prognostic subgroups:
Class I (60% of the cases)
Low metastatic risk :
IA (87%) almost without metastasis (0.8% of the patients).
IB (13%) few metastasis (10.8%) + disomy cr3 few metastasis.
Class II (40% of the cases)
High metastatic risk: metastasis (29.8%) + monosomy or pseudodisomy cr3 metastasis is not
sure, + Trisomy cr6: 80 % of patients will show metastasis 4 years after diagnosis.
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This classification might be helpful for the prognosis in three aspects: in the screening tar‐
geted to metastasis, in the earlier diagnosis of the metastasis and for an earlier preventing
treatment of the metastasis in high risk cases. In this regard, it is important to highlight that
there is no scientific evidence about increased survival due to metastasis treatment [47].
8. Uveal melanoma TNM staging and survival: Implications in patient
management and prognosis
Damato, B; Eleuteri, A [48] support the idea that Kaplan-Meier survival curves based only in
tumour size and extend do not provide a true indication of prognosis. This is because the
survival prognosis in uveal melanoma correlates not only with clinical stage but also with
histologic grade, genetic type and competing causes of death. They propose an online pre‐
dictor tool using the following data:
8.1. Parameters
Age
Sex
Large ultrasound diameter
Cilliary body involvement
Extraocular extension
Years since treatment
Epithelloid Cells
Closed PAS+ ve loops
Mitotic rate/40
Monosomy 3
Regional Lymph nodes
Distant metastasis
First scan (years)
Threshold for next scan (number)
8.2. TNM Stage
C.
Survival
Controls
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Subjects
Difference
Relative
9. Conclusion
The uveal melanoma, which arises from melanocytes residing in the stroma, is the most
common primary intraocular tumour in adults. More than 90% involve the choroid, the re‐
mainder being confined to the ciliary body and iris.
The most common symptoms in uveal melanoma include visual loss, photopsias and visual
field defects but none of these symptoms are specific of this malignancy. Diagnosis is based
on slit-lamp biomicroscopy and/or ophthalmoscopy, with ultrasonography, autofluores‐
cence photography. Although each day we count with more variety and helpful comple‐
mentary studies, suspicious lesions should be closely monitored. Uveal melanomas are
diverse in their clinical features and behaviour. Despite ocular treatment almost 50% of pa‐
tients with primary uveal melanoma will develop distance metastasis [50]. The metastatic
disease occurs almost exclusively in patients whose tumour show chromosome 3 loss and/or
class 2 gene expression profile. When the tumour shows such lethal genetic changes, the sur‐
vival time depends on the anatomical stage and the histological grade of the malignancy.
Prognostication has improved as a result of progress in multivariate analysis including all the
major risk factors.
Screening for metastases is more sensitive as a consequence of the advances in liver scan‐
ning with magnetic resonance imaging and other methods. More patients with metastases
are living longer, benefiting from therapies such as: partial hepatectomy; radiofrequency
ablation; ipilumumab immunotherapy; selective internal radiotherapy; intra-hepatic chemo‐
therapy, possibly with isolated liver perfusion; and systemic chemotherapy [48].
Conservation of the eye with useful vision has improved thanks to the advances in brachyther‐
apy, proton beam radiotherapy, transpupillary thermotherapy. The current trend is to try to
preserve the affected eye by all means, as there is no scientific evidence that shows that re‐
moving the affected eye will improve survival.. This is a great difference in the treatment of
ocular vs cutaneous melanoma. The specialists must take into consideration the need to pro‐
tect the eye with melanoma and preserve as much vision as possible as the other eye may be
affected by another pathology in the future with the consequent loss of vision.
On the basis of the currently available information it appears that patients treated with radi‐
otherapy have a survival rate at least as good, if not better than those treated with enuclea‐
tion [36].
Several drugs, such as bortezomib, celecoxib, dacarbazine, anti-angiogenic agents (such as
bevacizumab, sorafenib and sunitinib), temsirolimus, mitogen-activated protein kinase kin‐
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ase (MEK) inhibitors, ipilimumab and AEB071 are candidate drugs, and studies are under‐
way to determine the therapeutic effects of these drugs in uveal melanoma [51].
Currently, the aim is to improve the detection of uveal melanoma so as to maximize the op‐
portunities for conserving the eye and vision, as well as preventing metastatic spread. Pa‐
tient management has been enhanced by the formation of multidisciplinary teams in
specialized ocular oncology centers all over the world.
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